Evidence from Europe on implementation, participation and performance of self-collection for cervical cancer screeningFUTURE ONCOLOGYIF2.62024-10-240OA
Comparing the Costs and Diagnostic Outcomes of Replacing Cytology with the QIAsure DNA Methylation Test as a Triage within HPV Primary Cervical Cancer Screening in The NetherlandsDIAGNOSTICSIF3.32023-12-063OAAI
Determining the Relationship Between Seizure-Free Days and Other Predictors of Quality of Life in Patients with Dravet Syndrome and Their Carers from FFA Registration StudiesNEUROLOGY AND THERAPYIF4.82023-06-165OAAI
Assessing the clinical impact and resource use of a 30-minute chlamydia and gonorrhoea point-of-care test at three sexual health servicesTHERAPEUTIC ADVANCES IN INFECTIOUS DISEASEIF3.42021-12-022OAAI
Late Breaking Abstract - Analysing the COPD care pathway in Japan, Canada, England and Germany: pilot study resultsEUROPEAN RESPIRATORY JOURNALIF212021-11-250PRE
Antimicrobial resistance point-of-care testing for gonorrhoea treatment regimens: cost-effectiveness and impact on ceftriaxone use of five hypothetical strategies compared with standard care in England sexual health clinicsEUROSURVEILLANCEIF7.82020-10-296OAAI
Understanding the acceptability, barriers and facilitators for chlamydia and gonorrhoea screening in technical colleges: qualitative process evaluation of the Test n Treat trialBMC PUBLIC HEALTHIF3.62020-08-0813OAAI
'Test n Treat' (TnT): a cluster randomized feasibility trial of on-site rapid Chlamydia trachomatis tests and treatment in ethnically diverse, sexually active teenagers attending technical collegesCLINICAL MICROBIOLOGY AND INFECTIONIF8.52019-07-016OAAI
EVALUATING THE COSTS, BENEFITS AND COST-EFFECTIVENESS OF MULTI-PATHOGEN POINT-OF-CARE TESTS FOR SEXUALLY TRANSMITTED INFECTIONS IN SYMPTOMATIC GENITOURINARY MEDICINE CLINIC ATTENDEESSEXUALLY TRANSMITTED INFECTIONSIF2.92017-07-081OAAI
COST-EFFECTIVENESS OF ANTIMICROBIAL RESISTANCE POINT-OF-CARE TESTING FOR OPTIMISING THE TREATMENT OF GONORRHOEASEXUALLY TRANSMITTED INFECTIONSIF2.92017-07-080OA
Performance of a Novel Point-of-Care Molecular Assay for Detection of Influenza A and B Viruses and Respiratory Syncytial Virus (Enigma MiniLab) in Children with Acute Respiratory InfectionJOURNAL OF CLINICAL MICROBIOLOGYIF5.42016-01-0112OAAI
Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UKJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62014-12-2123OAAI
ESTIMATED COST AND PAYMENT BY RESULTS (PBR) TARIFF REIMBURSEMENT FOR IDIOPATHIC PULMONARY FIBROSIS SERVICES ACROSS 14 SPECIALIST PROVIDERS IN ENGLANDTHORAXIF7.72014-11-100OAAI
Guiding Postablative Lymphocyte Reconstitution as a Route Toward Transplantation ToleranceAMERICAN JOURNAL OF TRANSPLANTATIONIF8.22014-07-0112OAAI
Time to manage Mycoplasma genitalium as an STI: but not with azithromycin 1 g!CURRENT OPINION IN INFECTIOUS DISEASESIF42014-02-0160PREAI
An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine clinics in EnglandSEXUALLY TRANSMITTED INFECTIONSIF2.92013-11-2264OAAI
WHAT ARE THE CLINICAL AND ECONOMIC COSTS AND BENEFITS OF IMPLEMENTING POINT OF CARE TESTS FOR CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEA IN GENITO-URINARY MEDICINE CLINICS IN THE UNITED KINGDOM?VALUE IN HEALTHIF62013-11-010OAAI
THE IMPACT OF CHLAMYDIA AND GONORRHOEA POINT OF CARE NUCLEIC ACID AMPLIFICATION TESTS ON CLINICAL PATHWAYS AND COSTS IN GENITO-URINARY MEDICINE CLINICS IN THE UNITED KINGDOMVALUE IN HEALTHIF62013-11-010OAAI
COUNTING THE PENNIES: RATIONAL PRESCRIBING WITHIN THE CONTEXT OF THE NATIONAL CHLAMYDIA SCREENING PROGRAMMESEXUALLY TRANSMITTED INFECTIONSIF2.92013-07-130OAAI
CLINICAL CARE PATHWAYS USING CHLAMYDIA AND GONORRHOEA TESTS ARE EVOLVING: POINT OF CARE NUCLEIC ACID AMPLIFICATION TESTS MAY REDUCE GENITOURINARY MEDICINE SERVICE DELIVERY COSTSSEXUALLY TRANSMITTED INFECTIONSIF2.92013-07-131OAAI